CORPORATE MILESTONES

Below is a brief summary of the background of GeneMedix plc, highlighting key milestones in the company’s development.

Founded through a collaboration and joint venture with the Shanghai Institute of Biochemistry and Cell Biology [IBCB], GeneMedix sponsored research and subsequently acquired rights to the manufacture and sale of specified biopharmaceutical proteins using recombinant DNA technology.

February 2007	Acquisition by Reliance Life Sciences completed
January 2007	Acquisition by Reliance Life Sciences approved at EGM
August 2006	Letter of Intent signed with Reliance Life Sciences (RLS) for RLS to acquire a controlling interest in GeneMedix through a subscription of new shares.
October 2005	Restructuring programme commenced to re-finance the business and attract new corporate partners.
September 2005	Letter of intent signed to sell Chinese facility and restructuring programme announced
July 2005	G-CSF deal signed with CJ Pharma Draft guidelines published by EMEA for EPO, G-CSF and HGH
October 2004	Signed Southridge financing deal to raise up to $10 million equity over 3 years
June 2004	Agreement with Kryonix to supply GM-CSF to Russia
April 2004	New pharmaceutical directive introduced into European Union that establishes legal pathway for the registration of “follow-on” biologics
January 2004	Level One ADR programme established on NASDAQ and appointed Global Markets Capital for strategic M&A
June 2003	Letter of Intent signed with Penang Development Corporation to establish a Biotechnology Company in Penang, Malaysia for the development, manufacture and commercialisation of human insulin.
March 2003	New collaboration with Antares Pharma announced, with the aim of improving device technology for GeneMedix products.
February 2003	Formation of a Joint Venture with Antibioticos Group, involving construction of a state-of-the-art fermentation facility in Europe for contract manufacture of three products. Antibioticos is a worldwide market leader in the development and production of intermediates for the pharmaceutical industry.
July 2002	GeneMedix signs a Development Agreement for interferon alfa-2b with SkyePharma plc, who employ leading drug delivery technology to develop easier-to-use and more effective formulations of drugs.
June 2002	Official opening of GeneMedix plc's new manufacturing facility in Tullamore, Ireland. Guests included Brian Cowen, TD, Minister for Foreign Affairs in Ireland, pictured to the right with Paul Edwards, GeneMedix CEO, and Conor O'Dea, General Manager [Ireland].
May 2002	Agreements for Manufacturing and for Sales & Distribution signed with Gland Pharma Ltd, one of India's leading suppliers of speciality pharmaceutical products.
January 2002	Announcement of first product sales in China for GeneMedix plc's initial product, Neustim™.
2001	Leading Malaysian pharmaceutical manufacturer, Hovid SDN BhD, is appointed to distribute, market and sell GeneMedix's products within Malaysia and other ASEAN countries. GeneMedix received full regulatory approval from the Chinese State Drug Administration [SDA] to sell granulocyte macrophage colony stimulating factor [GM-CSF]. The company announces its plans to open a second manufacturing facility, in Ireland, for the manufacture of recombinant erythropoietin.
2000	Highlights included the acquisition of the company's first manufacturing facility, based in China. Earlier in the year, GeneMedix achieved a dual listing on the London and Singapore Stock Exchanges, raising £20m in addition to its initial funding. The company also recruited its core management team during this year.
1999	The first round of external funding for the company was sought, and Paul Edwards [formerly VP of Genzyme, UK] was appointed as GeneMedix plc's CEO.
1997	GeneMedix was founded as a company by Dr Kim Tan and Dr Hong-Hoi Ting [now Director, Asia for GeneMedix plc], with the Shanghai Institute of Biochemistry acting as a major shareholder.